Siemens' PETNET Solutions to Offer PET Prostate Tracer for Clinical Trials
· Company will manufacture, distribute 68Ga-labelled PSMA for prostate cancer PET imaging research in greater New York City area
In an effort to support positron emission tomography (PET) imaging techniques for the diagnosis and treatment of prostate cancer, Siemens’ PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, will provide clinical researchers in the greater New York City area with access to Gallium-68-Labelled Prostate-Specific Membrane Antigen (68Ga-labelled PSMA). This investigational tracer is being studied for prostate cancer imaging using PET/computed tomography (PET/CT) in clinical trials throughout the world.
Prostate cancer is the second most frequently diagnosed cancer among men in the United States. An estimated 220,000 men are expected to be diagnosed with the disease this year, with approximately 15,000 in New York state alone.1 Recent hypotheses regarding the variation and diversity of prostate cancer suggest that all variants should not be treated equally2 – underscoring a need for expanded classification of the disease through imaging and biopsy methods.
Contact for journalists
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide. Further information is available on the Internet at http://www.siemens.com.
1American Cancer Society, Cancer Facts & Figures 2015.
2Wyatt A.W., Mo, F., Wang, Y., & Collins, C.C. (2013). The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl. 15(3), 301-8.